Ionis Pharmaceuticals Inc IONS
News
Ionis Gets FDA Fast-Track Designation for Zilganersen in Alexander Disease
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Ionis announces pricing of $500.3 million public offering
Ionis announces proposed public offering of common stock
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
Ionis to present at upcoming investor conferences
Ionis reports second quarter 2024 financial results
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Ionis to hold second quarter 2024 financial results webcast
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
Alnylam's stock surges as heart drug vies with a Pfizer blockbuster
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
Ionis Pharmaceuticals, AstraZeneca Get FDA Approval for Rare Genetic Disease Treatment
Ionis, Roche Set New Pact Targeting Alzheimer's, Huntington's